New colorectal cancer treatment significantly reduces recurrence

Date:

Share this article:

Del denne artikel:

A clinical trial points to revised treatment strategies for colorectal cancer.

Traditionally, colorectal cancer is treated with surgery followed by chemotherapy, but newer clinical data suggest alternative sequencing, writes SciTechDaily.

In a UK phase trial, patients with stage II and III colorectal cancer were treated with immunotherapy before surgery.

Participants received up to nine weeks of treatment with pembrolizumab prior to surgery, after which their disease course was systematically monitored.

The UCL trial included 32 patients with a specific genetic profile, representing a small proportion of colorectal cancer cases.

Also read: Heavy metals found in oatmeal – cadmium in particular raises concerns

This subgroup is known to respond differently to treatment compared with other patients.

Biological mechanisms and monitoring

Alongside treatment, individualized blood tests were developed to measure circulating tumor DNA.

These analyses made it possible to identify early signs of treatment response and assess the risk of recurrence.

The results showed a clear correlation between the disappearance of tumor DNA in the blood and the absence of disease over time.

Also read: Researchers find a promising alternative to Ozempic using AI

In addition, immunoprofiling of tumor tissue was used to predict which patients were most likely to benefit from the treatment.

Implications for future treatment

Long-term follow-up over 33 months showed no cases of recurrence among participants, a marked contrast to standard treatment courses, where around a quarter of patients experience recurrence within three years.

At the same time, significant tumor reduction prior to surgery was observed in a large proportion of patients.

These results indicate that immunotherapy before surgery may change the prognosis for selected colorectal cancer patients and potentially reduce the need for subsequent treatment.

Also read: This is how much water you should drink every day

The timing of treatment may be crucial for long-term disease control in specific patient groups.

Sources: SciTechDaily and UCL.

Also read: These dreams recur among dying patients at night

This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.

Other articles

Taking Ozempic or Wegovy? The FDA just added a vision-loss warning to the label

Behind the label change is a single eye condition and a rate that quietly doubled compared with the trials' control groups.

Five breathing techniques that may calm anxiety in just a few minutes

All five patterns have research behind them, but one stood out for how fast it works.

How eating tomatoes every day may affect your heart and cancer risk

A cheap kitchen staple keeps showing up in major heart and cancer reviews, and the daily amount is smaller than you'd expect.

What your gums can reveal about your heart health and disease risk

What a dentist spots at your next checkup may say something about the blood vessels around your heart, not just about your teeth.

Taking Ozempic or Wegovy? The FDA just added a vision-loss warning to the label

Behind the label change is a single eye condition and a rate that quietly doubled compared with the trials' control groups.

Five breathing techniques that may calm anxiety in just a few minutes

All five patterns have research behind them, but one stood out for how fast it works.

How eating tomatoes every day may affect your heart and cancer risk

A cheap kitchen staple keeps showing up in major heart and cancer reviews, and the daily amount is smaller than you'd expect.